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The Roles of Cholesterol and Its
Metabolites in Normal and Malignant
Hematopoiesis
Hideyuki Oguro*
Cellular Engineering, The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States
Hematopoiesis is sustained throughout life by hematopoietic stem cells (HSCs) that
are capable of self-renewal and differentiation into hematopoietic progenitor cells
(HPCs). There is accumulating evidence that cholesterol homeostasis is an important
factor in the regulation of hematopoiesis. Increased cholesterol levels are known to
promote proliferation and mobilization of HSCs, while hypercholesterolemia is associated
with expansion of myeloid cells in the peripheral blood and links hematopoiesis with
cardiovascular disease. Cholesterol is a precursor to steroid hormones, oxysterols,
and bile acids. Among steroid hormones, 17β-estradiol (E2) induces HSC division and
E2-estrogen receptor α (ERα) signaling causes sexual dimorphism of HSC division
rate. Oxysterols are oxygenated derivatives of cholesterol and key substrates for
bile acid synthesis and are considered to be bioactive lipids, and recent studies
have begun to reveal their important roles in the hematopoietic and immune
systems. 27-Hydroxycholesterol (27HC) acts as an endogenous selective estrogen
receptor modulator and induces ERα-dependent HSC mobilization and extramedullary
hematopoiesis. 7α,25-dihydroxycholesterol (7α,25HC) acts as a ligand for Epstein-Barr
virus-induced gene 2 (EBI2) and directs migration of B cells in the spleen during the
adaptive immune response. Bile acids serve as chemical chaperones and alleviate
endoplasmic reticulum stress in HSCs. Cholesterol metabolism is dysregulated in
hematologic malignancies, and statins, which inhibit de novo cholesterol synthesis, have
cytotoxic effects in malignant hematopoietic cells. In this review, recent advances in our
understanding of the roles of cholesterol and its metabolites as signaling molecules in
the regulation of hematopoiesis and hematologic malignancies are summarized.
Keywords: cholesterol, oxysterols, steroids, hematopoietic stem cells, hematopoiesis, hematologic malignancies
INTRODUCTION
Hematopoietic stem cells (HSCs) sustain blood production throughout life and are the functional
units of bone marrow transplantation. HSCs are capable of self-renewal to maintain their pool
while producing all mature blood cells through differentiation intomultipotent progenitors (MPPs)
and subsequent hematopoietic progenitor cells (HPCs) with limited differentiation potentials
(Figure 1). In adult mice, all HSCs and MPPs fall within the Lineage marker−Sca-1+c-Kit+ (LSK)
fraction (1–3), which is a heterogeneous population that contains a mixture of hematopoietic
stem and progenitor cells (HSPCs), including HSCs, MPPs, and HPCs. HSCs can be further
purified by selecting the CD150+CD48−/low subset (4, 5) or CD34−/lowFlt3− subset (6, 7) of
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FIGURE 1 | Model of the hematopoietic hierarchy. A hierarchical structure of the adult hematopoietic system based on studies by us and others using mice. HSCs
reside at the top of the hierarchy and give rise to MPPs and potentially MEPs. MPPs generate HPCs and MEPs, and HPCs generate GMPs and CLPs. Mature cells
are developed from these oligopotent progenitors, MEPs, GMPs, and CMPs, through intermediate progenitors. Some lineage relationships are under debate.
LSK cells. The HSC population is functionally heterogenous
in terms of cell-cycle kinetics, self-renewal capacity, and
differentiation potential, and the heterogeneity can be
distinguished by additional markers such as CD229 (5) and
von Willebrand factor (8). Human HSPCs can be marked by
Lineage marker−CD38−CD34+ and the HSC population can
be further refined by marking the CD45RA−CD49f+ subset
of Lineage marker−CD38−CD34+ cells (9). HSCs reside in
specialized niches which are local tissue microenvironments
that support HSC behavior and regulate their function, such
as self-renewal, differentiation, and localization, by producing
factors that act directly on HSCs (10). In adults, HSCs are
quiescent and localize primarily in the bone marrow, and their
number is tightly regulated under steady-state conditions,
comprising <0.01% of bone marrow cells in mice. In response to
acute hematopoietic demands such as blood loss, myeloablation,
infection, or pregnancy, HSCs change two aspects of their
steady-state behaviors in order to increase production of
necessary hematopoietic cells (11–14). First, quiescent HSCs
re-enter the cell cycle to proliferate or differentiate through
symmetric or asymmetric cell divisions, and second, they
mobilize from the bone marrow to extramedullary tissues, such
as the spleen, to expand the physical space for hematopoiesis.
In addition to the regulation of HSC behaviors by short-range
factors, such as cytokines, cell-surface proteins, extracellular
matrix components, oxygen tension, and ion levels, that are
generated in their niches, HSCs are also regulated by long-range
systemic signals, such as circulating cytokines, hormones, lipids,
and vitamins. Cholesterol is found in the bloodstream and within
cells, and is an essential structural component of mammalian
plasma membranes and is essential to maintain both membrane
structural integrity and to modulate membrane fluidity (15).
Cholesterol also serves as a precursor for the biosynthesis of
steroid hormones, oxysterols, and bile acids (Figure 2) (16).
These cholesterol metabolites have important biological roles
as signal transducers and chemical chaperones, and there is
accumulating evidence that these metabolites act as systemic
signals that regulate normal and malignant hematopoiesis. This
review discusses recent advances in understanding the roles of




In the bloodstream, cholesterol is transported within lipoprotein
particles, which are organized by apolipoproteins that can be
recognized and bound by specific receptors on cell membranes.
There are several types of lipoproteins, such as high-density
lipoprotein (HDL), low-density lipoprotein (LDL), intermediate-
density lipoprotein (IDL), very-low-density lipoprotein (VLDL),
and chylomicrons, in order of higher density to lower density.
LDL is the major cholesterol carrier in the blood and is
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FIGURE 2 | Cholesterol synthetic/metabolic pathways. Pathways of cholesterol biosynthesis (top), bile acid biosynthesis (bottom left), and steroidogenesis (bottom
right) are presented. Enzymes that catalyze the conversions are shown adjacent to the arrows.
recognized by the LDL receptor (LDLR) in peripheral tissues.
LDL is the atherogenic lipoprotein, and increased LDL levels
promote cholesterol accumulation. Macrophages accumulate
oxidized LDL and give rise to foam cells, and contribute to
atherosclerotic plaque formation. HDL opposes this process and
reduces inflammation. HDL is involved in reverse cholesterol
transport, in which HDL serves to shuttle cholesterol from
peripheral tissues to the liver where cholesterol is eventually
converted into bile acids.
Hypercholesterolemia Induces
Proliferation and Mobilization of Mouse
Hematopoietic Stem and Progenitor Cells
Several studies have shown a strong correlation between
plasma cholesterol levels and the mobilized HSC number in
the peripheral blood using mouse models. Gomes et al. showed
that mice fed a high-fat/high-cholesterol (HFHC) diet for 30
days displayed thrombocytosis, lymphocytosis, and an increase
in the number of HSPCs mobilized into the peripheral blood,
while the HSPC number in the bone marrow decreased (17).
They also found that the HFHC diet induced increased plasma
levels of C-X-C motif chemokine ligand 12/ stromal cell-derived
factor 1 (CXCL12/SDF1), a chemokine which is chemotactic
for HSCs that express its receptor C-X-C motif chemokine
receptor 4 (CXCR4) (18). Apolipoprotein E (APOE) is a key
component in cholesterol metabolism and Apoe-deficient mice
cause hypercholesterolemia (19, 20). Apoe-deficient mice fed an
HFHC diet developed monocytosis (21–23), and Murphy et al.
also reported neutrophilia associated with the proliferation and
expansion of HSPCs in the bone marrow (23). Interestingly,
APOE was expressed on the surface of HSPCs and acted cell
autonomously to control HSPC proliferation, monocytosis,
neutrophilia, and monocyte accumulation in atherosclerotic
lesions, as revealed by transplantation of Apoe-deficient bone
marrow cells. LDLR deficiency causes impaired LDL clearance,
resulting in high plasma LDL-cholesterol levels and causing
familial hypercholesterolemia. LDL receptor-deficient (Ldlr−/−)
mice fed an HFHC diet displayed hypercholesterolemia
associated with increased HSPCs in both bone marrow and
peripheral blood, and increased monocytes and granulocytes in
the peripheral blood (24, 25). In addition to their mobilization,
more HSPCs in the bone marrow incorporated the DNA
synthesis marker 5-bromo-2′-deoxyuridine (BrdU) in Ldlr−/−
mice on an HFHC diet as compared to in Ldlr−/− mice on a
normal diet, indicating that hypercholesterolemia promoted
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HSPC proliferation. In contrast, infusion with reconstituted
HDL reduced the frequency and proliferation rate of HSPCs
in the bone marrow, highlighting the opposing effects of LDL
and HDL on HSPC proliferation. Scavenger receptor type
BI (SR-BI, encoded by Scarb1 gene) is a HDL receptor, and
Scarb1−/− mice showed increased plasma total cholesterol levels
with unchanged plasma concentration of apoA-I, the major
protein in HDL (26). Gao et al. reported that Scarb1−/− mice
fed an HFHC diet showed significantly increased the number
of HSPCs in the bone marrow, spleen, and peripheral blood,
as well as the proliferation of HSPCs as compared to wild-type
mice fed an HFHC diet (27). Interestingly, HSPCs in Scarb1−/−
mice fed an HFHC diet displayed increased levels of reactive
oxygen species (ROS). Elevation of ROS levels hinders HSC
quiescence and self-renewal, and accelerates HSC exhaustion
(28). Injection of ROS inhibitor N-acetylcysteine attenuated
HSPC expansion and leukocytosis in Scarb1−/− mice fed an
HFHC diet, suggesting a correlation between ROS levels and
HSPC proliferation. Tie et al. also reported that Apoe-deficiency
increased the number and ROS levels of HSPCs, and these were
further increased by the HFHC diet (29). They also observed
shorter telomere length in HSPCs in Apoe−/− mice as compared
to wild-type mice, suggesting accelerated aging of HSPCs, and
this phenotype was reversed by treating Apoe−/− mice with N-
acetylcysteine. These studies clearly indicate increased systemic
cholesterol levels promote proliferation and mobilization
of HSPCs.
Cholesterol Efflux Pathways Regulate
Proliferation and Mobilization of Mouse
Hematopoietic Stem and Progenitor Cells
ABCA1 and ABCG1, adenosine triphosphate-binding cassette
transporters, play a key role in promoting active cellular
cholesterol efflux (30). Yvan-Charvet et al. reported that
Ldlr−/− mice on an HFHC diet that were transplanted with
Abca1−/−Abcg1−/− bone marrow cells showed accelerated
atherosclerosis and extensive infiltration of myocardium
and spleen with macrophage foam cells as compared to
transplantation with wild-type bone marrow cells (31). The same
group subsequently reported that Abca1−/−Abcg1−/− mice on a
normal diet displayed five-fold increase of HSPCs (including the
CD34+CD150+Flt3− highly-pure HSC population) in the bone
marrow, as well as the increase in the S/G2/M fraction in HSPCs
(32). The overall BrdU incorporation of Abca1−/−Abcg1−/−
bone marrow cells was increased in vitro, whereas when wild-
type bone marrow cells were mixed with Abca1−/−Abcg1−/−
bone marrow cells, the overall BrdU incorporation of wild-type
bone marrow cells was not increased, suggesting that HSPC
proliferation in Abca1−/−Abcg1−/− mice was caused by cell
autonomous effects. Interestingly, in their next report, they
showed that Abca1−/−Abcg1−/− mice also displayed an increase
in HSPCs in the peripheral blood, spleen, and liver, indicating
HSPC mobilization and extramedullary hematopoiesis (33).
In this study, they performed a competitive bone marrow
transplantation experiment by transplanting a mixture of equal
numbers of bone marrow cells from wild-type and Abca1−/−
Abcg1−/− mice into wild-type recipient mice, and found that
HSPC mobilization of both the Abca1−/− Abcg1−/− and
wild-type donor cells was induced, suggesting that there is a
cell-extrinsic factor that induces HSPC mobilization of wild-type
donor cells fromAbca1−/−Abcg1−/− donor cells. Plasma levels of
granulocyte colony-stimulating factor (G-CSF) were significantly
increased in recipients of Abca1−/−Abcg1−/− bone marrow cells
and the mobilization of Abca1−/−Abcg1−/− HSPCs was reduced
by injection of G-CSF-neutralizing antibody. Interleukin-17
(IL-17) is a potent inducer of G-CSF (34), and the production
of IL-17 can be mediated by the secretion of interleukin-23
(IL-23) from splenic phagocytic macrophages and dendritic
cells (35). In the recipients of Abca1−/−Abcg1−/− bone marrow
cells, plasma G-CSF levels and colony-forming HSPC numbers
in the blood were normalized by an IL-17-blocking antibody,
and plasma levels of IL-17 and G-CSF, as well as colony-
forming HSPCs in the blood, were reduced by administration
of IL-23 receptor-neutralizing antibody. Both myeloid cell
(including macrophages) -specific and dendritic-cell specific
deletion of Abca1 and Abcg1 using lysM-cre; Abca1fl/fl; Abcg1fl/fl
mice, and CD11c-cre; Abca1fl/fl; Abcg1fl/fl mice, respectively,
exhibited increased levels of splenic IL-23, plasma IL-17 and
G-CSF, and colony-forming HSPCs in the blood, suggesting
that IL-23/IL-17/G-CSF signaling is associated with enhanced
HSPC mobilization in Abca1−/−Abcg1−/− mice. They further
reported that CXCL12 levels and the number of N-Cadherin+
osteoblasts, one of the CXCL12-expressing cell populations in
the bone marrow (36), were decreased in the bone marrow of
Abca1−/−Abcg1−/− mice, an effect that might be caused by
depletion of bone marrow macrophage populations due to an
enhanced IL-23/IL-17/G-CSF signaling axis. Thus, this study
supports a step-wise mechanism by which increased intracellular
cholesterol levels lead to mobilization of HSCs: (1) increased
cholesterol initially promotes secretion of pro-inflammatory
cytokines from immune cells, (2) this increases production of
G-CSF by bone marrow stromal cells, (3) reducing osteoblast
number and osteoblast production of CXCL12, a chemokine
which attracts HSCs, and (4) leads to HSC mobilization into
the bloodstream. They subsequently reported that Ldlr−/−
recipient mice that received lysM-cre; Abca1fl/fl; Abcg1fl/fl
bone marrow cells and were fed an HFHC diet developed
atherosclerosis associated with monocytosis and neutrophilia
(37). The authors demonstrated a cell-extrinsic mechanism
in which the expression of macrophage colony-stimulating
factor (M-CSF) and G-CSF were increased in the spleen, and




Cholesterol homeostasis also affects human hematopoiesis.
Crysandt et al. performed a retrospective analysis of a
variety of clinical parameters in 83 patients following high-
dose cyclophosphamide and G-CSF treatment and found that
patients with hypercholesterolemia showed a substantially higher
number of harvested CD34+ HSPCs in the peripheral blood
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as compared to normocholesterolemic patients (38). 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-
limiting enzyme of de novo cholesterol synthesis, and statins,
as inhibitors of HMG-CoA reductase, prevent the conversion of
HMG-CoA to L-mevalonate and inhibit downstream cholesterol
biosynthesis (Figure 2). Cimato et al. treated human subjects
with different statins, atorvastatin, pravastatin, and rosuvastatin,
to vary cholesterol levels and analyzed the number of mobilized
CD34+ HSPCs in the peripheral blood (39). They found a
positive correlation between CD34+ HSPC number and both
total and LDL-cholesterol levels. In addition, G-CSF and its
upstream regulator IL-17 both correlated positively with LDL-
cholesterol levels. Gao et al. studied the correlation between
HDL and white blood cell levels in patients with coronary heart
disease (27). They found negative correlations between HDL
levels and both total white blood cell and neutrophil counts in
the peripheral blood, and patients with low HDL-cholesterol had
more mobilized Lineage−CD34+CD38−CD45RA−/low HSCs in
the peripheral blood as compared to the patients with normal
HDL-cholesterol. Tolani et al. analyzed data from a clinical
trial of rosuvastatin in children with heterozygous familial
hypercholesterolemia and found that the children with the lowest
HDL-cholesterol levels had higher monocyte counts in the
peripheral blood, and there was an inverse correlation between
HDL levels and monocyte percentage (40). Thus, increased
cholesterol levels induce mobilization of not only mouse HSCs
but human HSCs, which suggests that cholesterol level is a
factor that should be considered when mobilizing HSCs for
clinical transplantation.
ROLES OF CHOLESTEROL METABOLITES
IN HEMATOPOIESIS
Sex Steroid Hormones
Estrogens and androgens are classically recognized as sex steroid
hormones, and progestogen are recognized as a third class of
sex steroid hormones. Each of these sex steroid hormones is
synthesized from cholesterol, and the first and rate-limiting step
of the steroidogenic pathway is the cleavage of the cholesterol
side chain by P450scc (CYP11A1) to convert into pregnenolone
(Figure 2) (41). Estrogens are produced in gonadal and extra-
gonadal tissues. In females, 17β-estradiol (E2), a most potent
estrogen, is produced primarily by theca and granulosa cells in
the ovaries. Androstenedione is generated from cholesterol and
is converted into testosterone by aromatase in theca cells, and
they are further converted into E2 by aromatase in granulosa
cells. Testosterone is the primary androgen secreted from Leydig
cells in the testes, and small amounts are also secreted from
theca cells in the ovaries. Progesterone is a critical progestogen
to establish and maintain pregnancy. Progesterone is produced
from cholesterol in the corpus luteum of the ovary during
early pregnancy and the production is sustained by the placenta
in humans and rodents. In addition to their well-recognized
effects on reproductive tissues, the sex steroid hormones are also
being recognized as having broad physiological effects on non-
reproductive tissues, such as nervous, cardiovascular, skeletal,
immune, and hematopoietic systems. It is known that females
and males differ in innate and adaptive immune responses, and
these sex-biased differences in the immune system contribute
to variations in the prevalence of autoimmune diseases and
malignancies, susceptibility to infectious diseases, and responses
to vaccines (42).
Androgens and Lympho-Hematopoiesis
Several studies have shown that androgens negatively regulate
B lymphopoiesis. Castration of male mice leads to spleen
enlargement and expansion of the B-cell population in the bone
marrow and spleen (43–45). This effect is reversed by androgen
replacement with either testosterone or dihydrotestosterone
(DHT) (46). Androgen-resistant “testicular feminization”
mutant male mice also show expansion of B-cell populations
in the bone marrow and spleen (45, 47). In addition to the
regulation of B lymphopoiesis, castrated mice and testicular
feminization male mice also show thymic hypertrophy,
which can be rescued by DHT administration (43, 45, 48–
50). Experiments transplanting wild-type bone marrow
cells into testicular feminization male mice suggest that
androgen receptors expressed by bone marrow stromal cells
or thymic epithelium modulate B-cell development or thymus
size, respectively (50, 51). Velardi et al. showed that one
mechanism by which androgens influence thymopoiesis is
through direct inhibition of the Notch ligand Dll4 in cortical
thymic epithelial cells (52). Immune function progressively
declines with age in mice and humans (53). In male mice,
castration rejuvenates aged bone marrow and thymus, enhances
peripheral T- and B-cell functions, and promotes immune
recovery following chemotherapy-induced immunodepletion
and HSC transplantation (54–62). These studies indicate that
androgens are critical mediators of age-related lymphoid decline.
Castration also enhances the recovery of bone marrow-resident
HSCs after chemotherapy-induced immunodepletion (62).
Khong et al. demonstrated that the number of HSCs marked
by CD34−Flt3−LSK was significantly increased at 7 days after
castration of 9-month-old mice as compared to sham-treated
mice, and the repopulation potential during serial bone marrow
transplantations was enhanced when using these mice as donors
(63). Their gene expression analyses suggest that castration
induces qualitative changes in both HSCs and their bone
marrow environment.
Estrogens and Lympho-Hematopoiesis
B lymphopoiesis in the bone marrow and T lymphopoiesis
in thymus are drastically reduced during pregnancy (64,
65). Ovariectomy stimulates B lymphopoiesis and results in
increased numbers of B cells in the bone marrow (66, 67),
and it is reversed by administration of E2 (68). Genetically
hypogonadal female mice which have a partial deletion of
the hypothalamic gonadotropin-releasing hormone gene have
a secondary deficiency in gonadal steroidogenesis and show
expansion of B cell progenitors. Estrogen replacement with E2
reversed the increased numbers of B cell progenitors in these
hypogonadal mice (69). Exogenous E2 treatment suppresses B
cell development in both male and female mice (68, 70, 71).
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Very early lymphoid precursors marked by Lineage marker−IL-
7Rα+c-KitloTerminal dexynucleotidyl transferase+ in the bone
marrow are selectively depleted by exogenous E2 treatment
(72). Both stromal-dependent and independent pathways of
estrogen action on developing B cells have been postulated. It
is proposed that bone marrow stromal cells expressing estrogen
receptors mediate negative regulatory effects of E2 on early
pre-B development (47, 73). A study of estrogen receptor
α (ERα) male knockout mice by Thurmond et al. indicated
that ERα is necessary for development of normal numbers
of B cells in the bone marrow (74). They investigated the
effect of E2 on lymphopoiesis by performing bone marrow
transplantation using ERα-deficient mice as donors, recipients,
or both, and treated with E2. They demonstrated that exogenous
E2-induced alteration of B cell populations was primarily caused
by a hematopoietic cell-intrinsic mechanism rather than by
their environment.
Estrogens also regulate other hematopoietic lineages.
Administration of a high-dose of estrogen induces anemia in
rodents and dogs, regardless of their sex (75–77). Schroeder
et al. reported that E2 sustained proliferation of erythroid
progenitors from chick bone marrow, but E2 also caused
erythroid differentiation arrest and blocked erythrocyte gene
expression (78). Blobel et al. also showed that E2 added to
the culture also reduced the number of erythroid progenitors
from human bone marrow (79). They demonstrated that
the transcriptional activity of GATA1, an erythroid master
transcription factor that is necessary for full maturation of
erythrocytes, was strongly repressed by direct binding of ER
in an E2-dependent manner in NIH 3T3 and COS cell lines.
The same group subsequently reported that inhibition of
GATA1 activity by ER induced apoptosis in a murine Friend
virus-induced erythroleukemia cell line (80). E2 treatment also
stimulates the megakaryocyte colony formation potential of
CD34+ human cord blood cells in vitro (81). E2 promotes
megakaryocyte polyploidization and maturation via activation of
ERβ accompanied by a significant upregulation of the expression
of GATA1, which is also a key regulator of megakaryocyte
differentiation (82). Differentiation of dendritic cells with
characteristics of Langerhans cells from myeloid progenitors
in culture, as induced by granulocyte-macrophage colony-
stimulating factor (GM-CSF), is promoted by addition of E2 and
inhibited by ER antagonists and ERα-deficiency (83). Interferon
regulatory factor 4 (IRF4), a transcription factor induced by
GM-CSF and critical for Langerhans cell development, is a
target of ERα signaling during this process (84). In contrast,
E2 significantly inhibits Flt3-ligand-induced plasmacytoid
and conventional dendritic-cell differentiation in culture by
decreasing numbers of viable differentiated cells (85). Thus,
the effects of E2 are likely to be dependent on the cytokine
pathways that might be operative in the steady state or during
inflammation and disease.
Estrogens Regulate HSC Division Rate
Estrogens also regulate HSC behavior. In our previous study,
we observed that HSCs divide more often in female mice as
compared to male mice (14). Ovariectomy in females (which
depletes both estrogens and progesterone) significantly reduced
HSC division to male levels, while castration of males has no
effect on HSC division. Conversely, administration of exogenous
E2, but not progesterone or dihydrotestosterone, significantly
increased HSC division in both female and male mice. Because
E2 treatment also increased HSC division in ovariectomized
female mice and castrated male mice, its action is independent
of the gonads. Although HSC division rate was increased in
untreated female mice as compared to male mice and in
E2-treated mice of either sex as compared to vehicle-treated
control mice, we did not observe an increase in absolute HSC
numbers in those untreated female mice or E2-treated mice.
Instead, we observed an increased generation of megakaryocyte-
erythroid progenitors (MEPs) in female mice as compared to
male mice, and increased splenic erythropoiesis in E2-treated
mice of both sexes as compared to vehicle-treated control
mice. Given that increased myeloid progenitors including MEPs
may arise directly from the asymmetric division of HSCs
(Figure 1) (86), our observations raise the possibility that the
increased MEPs in female mice reflects increased asymmetric
division of an HSC to produce one HSC and one MEP in
response to E2. ERα, but not ERβ, is highly expressed by
HSCs. Conditional deletion of Esr1, which encodes ERα, from
hematopoietic cells significantly reduced the HSC division rate
in female mice, but not in male mice. Esr1-deficient HSCs of
both sexes were insensitive to exogenous E2 treatment.Moreover,
E2 treatment of chimeric recipient mice transplanted with
equal numbers of wild-type and Esr1-deficient hematopoietic
cells revealed that E2 significantly induced division of wild-
type HSCs but not Esr1-deficient HSCs in the same recipient
mice, indicating that E2 acts directly on HSCs, rather than
acting indirectly by stimulating secondary signals from other
cells. E2 levels increase in females during pregnancy (87),
when extramedullary hematopoiesis is induced to increase the
production of red blood cells. Notably, pregnant mice exhibit
significantly increasedHSC division rate relative to non-pregnant
female mice, and the deletion of Esr1 in hematopoietic cells
significantly reduced the normal increase in HSC division
during pregnancy (Figure 3). Increased spleen size is observed
during pregnancy in mice and humans (88, 89). In addition
to the increased HSC division rate, we found that pregnant
mice exhibited significantly increased cellularity, erythropoiesis,
myelopoiesis, and HSC number in the spleen, indicating
extramedullary hematopoiesis and HSC mobilization, and these
processes also depend upon ERα function in HSCs. Pregnant
mice also had increased absolute HSC numbers in the bone
marrow, but deletion of Esr1 in hematopoietic cells did not
reverse this phenomenon, suggesting the existence of ERα-
independent factor(s) that increase(s) HSC numbers in pregnant
mice. Nevertheless, ERα signaling is critical for the induction of
HSC division and mobilization to the spleen for the expansion of
splenic erythropoiesis.
Illing et al. also reported the effects of E2 on HSC function
(90). In this study, they treated mice with E2 at a dose of
0.24 mg/kg/day for 30 days, which is a higher dose and longer
treatment than our study at a dose of 0.1 mg/kg/day for 7
days. In this condition, they observed a profound reduction
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FIGURE 3 | E2 and 27HC differentially regulate HSC division and mobilization
during pregnancy. Pregnancy upregulates E2–ERα and 27HC–ERα signaling.
E2–ERα signaling induces HSC division in the bone marrow. 27HC–ERα
signaling induces HSC mobilization into the circulation and spleen, and
augments splenic erythropoiesis.
in bone marrow cellularity by E2 treatment. E2 treatment
caused more HSPCs to enter the S phase. They also observed
an increased frequency of long-term reconstituting HSCs in
E2-treated mice by performing bone marrow transplantation
with a limiting dilution assay. However, donor-derived HSPCs
of the bone marrow of the recipient mice after tertiary
transplantation was decreased in the recipients that received
bone marrow cells from E2-treated mice, suggesting exhaustion
of reconstituting cells during serial transplantation. Deletion
of Esr1 reversed the reduction of bone marrow cellularity
by E2 treatment, however it did not reverse the increased
frequency of long-term reconstituting HSCs by E2 treatment.
Sanchez-Aguilera et al. reported the effect of tamoxifen, a
selective estrogen receptor modulator (SERM), on HSC function
(91). Tamoxifen induced HSC division as well as apoptosis in
MPPs, and these effects are mediated by ERα but not by ERβ.
Tamoxifen treatment significantly reduced MPP number, but
not HSC number, and compromised activation of hematopoiesis
after chemotherapy. They observed increased expression of
Myc in HSCs after tamoxifen treatment, and Myc-deficient
MPPs did not undergo apoptosis upon tamoxifen treatment.
Interestingly, female immunodeficient recipient mice support
reconstitution of the blood system by transplanted human
HSCs more efficiently than male immunodeficient recipient
mice (92, 93). Since female mice have higher E2 levels than
male mice and E2 induces HSC division, it is anticipated
that higher E2 levels in female recipient mice will promote
proliferation and differentiation of transplanted HSCs as
compared to male recipient mice with very low E2 levels.
The molecular mechanisms by which E2 regulates HSCs are
not fully understood. Chapple et al. proposed that HSCs from
mice treated with E2 had increased regenerative capacity after
transplantation or irradiation (94). They demonstrated that
E2–ERα signaling induced expression of Ern1, which encodes
Ire1α, to activate the Ire1α-Xbp1 pathway of the unfolded




Oxysterols are oxygenated derivatives of cholesterol and
key substrates for bile acid synthesis (Figure 2) (16). In
the classic pathway of bile acid synthesis, cholesterol is
converted into 7α-hydroxycholesterol (7αHC) by cholesterol
7α-hydroxylase CYP7A1, a rate limiting step that occurs
in the liver. In alternative pathways that occur primarily
in extrahepatic tissues, cholesterol is converted into 24-
hydroxycholesterol (24HC), 25-hydroxycholesterol (25HC), and
27-hydroxycholesterol (27HC) by cholesterol 24-hydroxylase
CYP46A1, cholesterol 25-hydroxylase CH25H, and sterol 27-
hydroxylase CYP27A1, respectively. Oxysterols are considered
to be bioactive lipids and recent studies have started to
reveal their important roles in both the hematopoietic and
immune systems. 27HC is the most abundant circulating
oxysterol and acts as an endogenous SERM which can
bind to ERs and regulate their function (95). Plasma 27HC
levels strongly correlate with total cholesterol levels (96), as
27HC is generated directly from cholesterol by the sterol
27-hydroxylase CYP27A1. Plasma 27HC levels are greatly
reduced in Cyp27a1-deficient mice (97). CYP27A1 is abundant
in the liver, but it is also expressed in extrahepatic tissues
(16). Dietary or genetic changes that elevate 27HC levels
modulate ER activity, thereby inhibiting vascular repair in
cardiovascular disease (95), promoting ER-positive breast
cancer growth (98, 99), and increasing the severity of
atherosclerosis (100).
We have demonstrated that the increases in HSC division,
HSC mobilization, and extramedullary hematopoiesis during
pregnancy require ERα in HSCs, and E2 treatment induces
HSC division as described above (14). Interestingly, our recent
study revealed that treatment of mice with E2 did not increase
HSC number in the spleen, indicating that E2 treatment does
not induce HSC mobilization (101). In contrast, treatment
with 27HC, another endogenous ER ligand, increased HSC
number in the spleen but not HSC division in the bone
marrow, indicating a role in inducing HSC mobilization. We
demonstrated that the effect of 27HC on HSC mobilization is
nullified by deletion of Esr1 in hematopoietic cells, indicating that
27HC-induced HSC mobilization is dependent on ERα. Plasma
cholesterol levels increase in humans during pregnancy (102).
During pregnancy in mice, we observed significant increases in
27HC levels in HSPCs. Cyp27a1-deficient mice had significantly
reduced HSC mobilization and extramedullary hematopoiesis
during pregnancy, while the increased rate of HSC division in
the bone marrow during pregnancy was not affected. These
findings indicate that 27HC acts in concert with E2 to promote
hematopoiesis during pregnancy by regulating ERα signaling
in HSCs (Figure 3). As described above, increased cholesterol
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levels promote HSC mobilization in mice and humans, and
increased HSC mobilization in Abca1−/−Abcg1−/− mice is
associated with elevated serum G-CSF levels (33). In our study,
we observed that 27HC treatment significantly induced HSC
mobilization in mice deficient for Csf3, which encodes G-
CSF (101). Together, 27HC and G-CSF additively increased
the numbers of colony-forming HSPCs in the peripheral
blood. Therefore, 27HC and G-CSF likely act through distinct
mechanisms to induce HSC mobilization. These findings suggest
an alternative model that the ability of elevated cholesterol
levels to promote HSC mobilization is mediated by increases
in 27HC production, because treating mice with 27HC induces
HSC mobilization and 27HC levels increase as cholesterol
levels increase.
E2, 27HC, and ERα
ERα is a nuclear receptor transcription factor and E2 is the
most potent endogenous estrogen. Different ER ligands are
known to have distinct effects on ERα-mediated regulation
of gene expression, and ER ligands differ in their structures
and their effects on ER conformation (103–106). For example,
Wardell et al. used breast cancer cell lines to test E2 and
five different synthetic ER ligands and observed different gene
expression patterns regulated by different ER–ligand complexes
(106). 27HC induces a unique conformational change in the ER
that is different from that mediated by E2 and other ER ligands
(107). Different ER–ligand complexes also engage functionally
distinct coregulators by selective recruitment of coactivators
and corepressors to activate and repress expression of target
genes, respectively (108). Thus, as different ER ligands can
act through the ERα to differentially regulate gene expression,
this may explain why E2 and 27HC have distinct effects
on HSCs even though both act through ERα (Figure 3). It
will be interesting to explore the nature of the ERα target
genes as well as the mechanism by which ERα function is
differentially regulated by E2 and 27HC, two major endogenous
ER ligands.
Bile Acids
Bile acids are synthesized from cholesterol in the liver
(Figure 2), secreted into the bile, and delivered to the lumen
of the small intestine where they act as emulsifiers of dietary
lipids, cholesterol, and fat-soluble vitamins (16). However,
bile acids have additional roles (109). Tauroursodeoxycholic
acid (TUDCA) serves as a chemical chaperone and reduces
endoplasmic reticulum stress (110). HSCs are predisposed
to apoptosis through misfolded protein accumulation in the
endoplasmic reticulum caused by cellular stress that subsequently
activates the unfolded protein response (111). Addition of
TUDCA to cultured mouse HSCs alleviates endoplasmic
reticulum stress and increases their capacity to reconstitute the
hematopoietic system in recipient mice upon transplantation
(112). In contrast to the quiescent state of adult HSCs in
the bone marrow, HSCs undergo a rapid expansion in the
fetal liver during development (113). Adult HSCs in the bone
marrow have a lower rate of protein synthesis as compared
to most other hematopoietic cells (114). Sigurdsson et al.
reported that although fetal-liver HSCs had a higher rate of
protein synthesis as compared to adult HSCs in the bone
marrow, fetal-liver HSCs had lower expression of endoplasmic
reticulum stress response genes (115). In addition to the role
of CYP27A1 for side chain oxidation of cholesterol for the
generation of 27HC to initiate the alternative acidic bile acid
biosynthetic pathway, CYP27A1 also catalyzes another side chain
oxidation after the ring modification step of both classic and
alternative acidic bile acid synthesis pathways (Figure 2) (16).
Cyp27a1-deficient mice have significantly decreased bile acids
(97). Sigurdsson et al. also reported that fetuses in Cyp27a1-
deficient mothers displayed significantly reduced levels of total
bile acids as wells as secondary bile acids in the fetal liver,
suggesting that maternal bile acids are transferred to the fetus
during pregnancy (115). Interestingly, the livers of Cyp27a1-
deficient fetuses in Cyp27a1-deficient mothers contained a
significantly lower number of long-term reconstituting HSCs, as
assessed by limiting dilution transplantation assay, and these fetal
HSCs showed significantly higher levels of protein aggregation.
These findings imply that bile acids enable fetal-liver HSCs to
have a higher level of protein synthesis without activating a
stress response, allowing expansion of the HSC pool during
fetal development.
25-Hydroxycholesterol
25HC is generated directly from cholesterol by CH25H, and
25HC is further converted into 7α,25-dihydroxycholesterol
(7α,25HC) by the oxysterol 7α-hydroxylase CYP7B1-mediated
hydroxylation (Figure 2) (116). Expression of Ch25h is
upregulated in macrophages and dendritic cells when they
are exposed to various inflammatory mediators (117–120).
25HC augments the production of inflammatory cytokines
in macrophages, and mediates feedback inhibition of
IL1b expression and inflammasome activation in activated
macrophages in the DNA sensor protein absent in melanoma 2
(AIM2)-dependent manner (121–124). 25HC is strongly induced
following viral infection and by interferon, and it inhibits the
replication of a wide range of enveloped viruses (125, 126).
25HC also promotes macrophage foam cell formation (127).
Epstein-Barr virus-induced gene 2 (EBI2), a G protein-coupled
receptor also known as GPR183, controls follicular B-cell
migration and T-cell-dependent antibody production (128, 129).
7α,25HC acts as a ligand for EBI2 and directs migration of B cells
in the spleen during the adaptive immune response (130, 131).
EBI2 and 7α,25HC also regulate splenic CD4+ dendritic cells for
positioning in marginal zone bridging channels to maintain their
homeostasis and mount a response against certain antigens, and
positioning of activated CD4T cells at the interface of the follicle
and T zone to interact with activated dendritic cells (132–134).
Thus, 25HC broadly regulates innate and adaptive immune
cell behavior. The 7α,25HC/EBI2 axis also regulates bone mass
homeostasis (135). EBI2 is expressed in monocyte/osteoclast
precursors, and 7α,25HC is secreted by osteoblasts. EBI2 guides
osteoclast precursors toward bone surfaces by promoting their
movement and positioning, which facilitates fusion of osteoclasts
and enhances the development of large osteoclasts to maintain
bone mass homeostasis.
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CHOLESTEROL SYNTHESIS/METABOLISM
AND HEMATOLOGIC MALIGNANCIES
Cholesterol metabolism is dysregulated in hematologic
malignancies. The rate of cholesterol synthesis is higher in
cells from acute myeloid leukemia (AML) patients as compared
to healthy subjects (136). Hypocholesterolemia is frequently
observed due to elevated LDL uptake by leukemia cells (137–
139), but elevated cholesterol levels in leukemia cells have
also been reported (140–143). Yvan-Charvet et al. reported
that HFHC diet administered Ldlr+/− mice transplanted with
cellular cholesterol efflux pathway-deficient Abca1−/−Abcg1−/−
bone marrow cells displayed a myeloproliferative neoplasm
(MPN)-like phenotype, and expression of an APOA1 transgene
that elevates HDL levels suppressed this phenotype (32).
Thus, changes in intracellular cholesterol levels are associated
with the development and maintenance of hematologic
malignancies. Statins have cytotoxic effects in various types
of malignant hematopoietic cells including AML (144–158),
chronic myeloid leukemia (CML) (153, 159–161), MPNs
(162), acute lymphocytic leukemia (ALL) (163, 164), chronic
lymphocytic leukemia (CLL) (165–167), adult T-cell leukemia
(ATL) (168), lymphoma (169, 170), and multiple myeloma
(171–176). To identify compounds that can inhibit the stem
cell activity of leukemia-initiating cells (LICs), Hartwell et al.
performed a high-throughput screen in a bone marrow-
mimicking culture system in which LICs expressing the
MLL-AF9 fusion oncogene were co-cultured with a bone
marrow stromal cell line (177). Among the compounds that
selectively inhibited LICs but not normal HSPCs, lovastatin
also inhibited LIC stem cell activity in an in vivo bone marrow
transplantation model. Although these reports demonstrate
the effectiveness of statins, the mechanisms of their anticancer
effects are not fully understood. Griner et al. reported that
MPN-associated JAK2V617F localized to lipid rafts, subdomains
of the plasma membrane that contain protein receptors
and a high concentration of cholesterol, and simvastatin
inhibited this localization and JAK2V617F-dependent cell growth
in MPN model cell lines (162). Simvastatin also inhibited
erythroid colony formation of primary cells from MPN
patients, but had no effect on cells from healthy individuals.
Other than the cholesterol-lowering effect, inhibition of the
mevalonate pathway by statins also reduces the levels of
farnesyl pyrophosphate and geranylgeranyl pyrophosphate and
thereby inhibits protein farnesylation and geranylgeranylation,
modifications that are important for a variety of cellular
processes including cell proliferation, survival, and migration
(Figure 2). Thus, the anticancer effects of statins could also
be rendered through changes in these other cellular processes
(157, 158, 170, 176).
Among the metabolites of cholesterol, oxysterols such
as 7βHC, 25HC, 7β,25HC, 7-ketocholestanol, and 7-
ketocholestanol have cytotoxic effects on leukemia and
lymphoma cells (178–183). Tsujioka et al. reported that
DNA methyltransferase inhibitors induced CH25H expression
with enhanced 25HC production and promoted apoptosis in
leukemia and myelodysplastic syndrome (MDS) cell lines, while
exogenous 25HC treatment suppressed cell growth of leukemia
andMDS cell lines (184). Other than oxysterol, Sanchez-Aguilera
et al. reported that tamoxifen treatment blocked development
of JAK2V617F-induced MPN in mice and induced apoptosis of
human MPN cells from patients with JAK2V617F mutation in a
xenograft model (91). They also demonstrated that tamoxifen
treatment reduced leukemic burden in a mouse model of AML
using mice transplanted with bone marrow cells expressing
the MLL-AF9 oncogene. Their findings have uncovered the
potential role of estrogen signaling in leukemia and suggest
the potential use of SERMs as a treatment for leukemia. The
roles of cholesterol metabolites in hematologic malignancies
are not yet fully explored, and further studies of cholesterol
metabolites are expected to elucidate their roles in hematologic
malignancies and their potential in preventing and treating
hematologic malignancies.
CONCLUSION AND FUTURE DIRECTIONS
Cholesterol and its metabolites are now being recognized to have
important roles in broad biological processes by regulating a wide
variety ofmolecularmachinery. Advances in understanding these
molecular mechanisms will benefit human health. One potential
clinical application of molecules that regulate or are regulated
by cholesterol metabolism is to enhance mobilization of HSCs
for transplantation. To enable efficient collection of mobilized
HSCs from the peripheral blood for HSC transplantation, donors
are treated with HSC-mobilizing agents such as G-CSF (185).
However, a significant proportion of donors fail to reach the
minimum HSC collection threshold required for transplantation
using traditional strategies (186). The failure of mobilization
can increase patient morbidity because patients cannot proceed
to transplantation. Thus, advances in mobilization strategies
that could increase the success of HSC collection without
introducing additional side effects are needed to improve patient
outcomes. For example, administration of 27HC enhances the
mobilization of HSPCs by G-CSF (101). Identification of the
genes downstream of 27HC-ERα signaling that mediate HSC
mobilization may contribute to the development of newmethods
that improve the yield of mobilized HSCs for transplantation,
while also offering an explanation for the long-standing
observation that increased cholesterol levels are associated with
increased HSC mobilization in mice and humans.
High blood cholesterol levels are associated with the
development of atherosclerosis. Atherosclerosis is a progressive
disease in which the inside of the artery become thick and stiff
due to the buildup of the atheromatous plaque which consists
of cholesterol, fat and other substances, and restricts blood
flow and causes complications including myocardial infarction,
peripheral artery disease, and stroke. In addition to lipids,
various types of leukocytes also accumulate in the atheromatous
plaque. Hypercholesterolemia causes monocytosis, and these
monocytes give rise to macrophages which eventually turn
into foam cells by ingesting LDL in the plaque, and promotes
plaque growth and inflammation. Other than monocytes,
diverse immune-cell subsets, such as neutrophils, mast cells,
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B and T lymphocytes, are associated with atherosclerosis
[reviewed in (187, 188)]. Oxysterols are formed and accumulate
in the plaque as a result of LDL oxidation due to the
inflammatory response. Although atherosclerotic properties
of oxysterols have been tested, it is still unclear whether
oxysterols have pro- or anti-atherosclerotic properties [reviewed
in (189)]. Estrogens also affect atherogenesis. Despite of
reports that support the atheroprotective effects of estrogens,
it is also controversial whether they have pro- or anti-
atherosclerotic properties [reviewed in (190)]. After myocardial
infarction, monocyte recruitment is increased, and sustained
and accelerated atherosclerosis is observed in a mouse model.
Interestingly, myocardial infarction causes HSPC mobilization
into the spleen and sustains augmented monocytepoiesis,
providing a possibility of novel therapy to mitigate progression of
atherosclerosis (191, 192). Thus, cholesterol and its metabolites
link hematopoiesis with cardiovascular health, and deciphering
this link is critical for developing new targeted therapies.
The molecular mechanisms underlying the regulation
of normal and malignant hematopoiesis by cholesterol
and its metabolites are not yet fully understood. There are
many drugs that target cholesterol synthetic and metabolic
pathways, and further studies are expected to generate
novel strategies for enhancing hematopoiesis, augmenting
hematopoietic recovery after hematopoietic injuries, improving
collection of mobilized HSCs for transplantation, and treating
hematologic malignancies.
AUTHOR CONTRIBUTIONS
The author confirms being the sole contributor of this work and
has approved it for publication.
FUNDING
The study was supported by The Jackson Laboratory and the
National Blood Foundation Scientific Research Grants Program.
ACKNOWLEDGMENTS
The author gives appreciation to colleagues and collaborators,
and apologizes to researchers whose work could not be cited
and this review owing to space limitations. The author thanks
Carmen Robinett for thoughtful editing of the manuscript.
REFERENCES
1. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization
of mouse hematopoietic stem cells. Science. (1988) 241:58–62.
doi: 10.1126/science.2898810
2. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T.
Enrichment and characterization of murine hematopoietic stem cells that
express c-kit molecule. Blood. (1991) 78:1706–12.
3. Ikuta K,Weissman IL. Evidence that hematopoietic stem cells express mouse
c-kit but do not depend on steel factor for their generation. Proc Natl Acad
Sci USA. (1992) 89:1502–6. doi: 10.1073/pnas.89.4.1502
4. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM
family receptors distinguish hematopoietic stem and progenitor cells
and reveal endothelial niches for stem cells. Cell. (2005) 121:1109–21.
doi: 10.1016/j.cell.2005.05.026
5. Oguro H, Ding L, Morrison SJ. SLAM family markers resolve
functionally distinct subpopulations of hematopoietic stem cells
and multipotent progenitors. Cell Stem Cell. (2013) 13:102–16.
doi: 10.1016/j.stem.2013.05.014
6. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-
term lymphohematopoietic reconstitution by a single CD34-
low/negative hematopoietic stem cell. Science. (1996) 273:242–5.
doi: 10.1126/science.273.5272.242
7. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem
cell differentiation: a simple method to isolate long-term stem cells.
Proc Natl Acad Sci USA. (2001) 98:14541–6. doi: 10.1073/pnas.2615
62798
8. Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, et al.
Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell
hierarchy. Nature. (2013) 502:232–6. doi: 10.1038/nature12495
9. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of
single human hematopoietic stem cells capable of long-term multilineage
engraftment. Science. (2011) 333:218–21. doi: 10.1126/science.1201219
10. Crane GM, Jeffery E,Morrison SJ. Adult haematopoietic stem cell niches.Nat
Rev Immunol. (2017) 17:573–90. doi: 10.1038/nri.2017.53
11. Cheshier SH, Prohaska SS, Weissman IL. The effect of bleeding on
hematopoietic stem cell cycling and self-renewal. Stem Cells Dev. (2007)
16:707–17. doi: 10.1089/scd.2007.0017
12. Randall TD,Weissman IL. Phenotypic and functional changes induced at the
clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood.
(1997) 89:3596–606.
13. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent
haematopoietic stem cells are activated by IFN-gamma in response to
chronic infection. Nature. (2010) 465:793–7. doi: 10.1038/nature09135
14. Nakada D, Oguro H, Levi BP, Ryan N, Kitano A, Saitoh Y, Takeichi M,
Wendt GR, Morrison SJ. Oestrogen increases haematopoietic stem-cell
self-renewal in females and during pregnancy. Nature. (2014) 505:555–8.
doi: 10.1038/nature12932
15. Ikonen E. Cellular cholesterol trafficking and compartmentalization.Nat Rev
Mol Cell Biol. (2008) 9:125–38. doi: 10.1038/nrm2336
16. Russell DW. The enzymes, regulation, and genetics of
bile acid synthesis. Annu Rev Biochem. (2003) 72:137–74.
doi: 10.1146/annurev.biochem.72.121801.161712
17. Gomes AL, Carvalho T, Serpa J, Torre C, Dias S. Hypercholesterolemia
promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4
axis. Blood. (2010) 115:3886–94. doi: 10.1182/blood-2009-08-240580
18. Karpova D, Bonig H. Concise review: CXCR4/CXCL12 signaling in
immature hematopoiesis–lessons from pharmacological and genetic models.
Stem Cells. (2015) 33:2391–9. doi: 10.1002/stem.2054
19. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG,
et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-
deficient mice created by homologous recombination in ES cells. Cell. (1992)
71:343–53. doi: 10.1016/0092-8674(92)90362-G
20. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous
hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.
Science. (1992) 258:468–71. doi: 10.1126/science.1411543
21. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R,
Pittet MJ. Ly-6Chi monocytes dominate hypercholesterolemia-associated
monocytosis and give rise to macrophages in atheromata. J Clin Invest.
(2007) 117:195–205. doi: 10.1172/JCI29950
22. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al.
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to
accumulate within atherosclerotic plaques. J Clin Invest. (2007) 117:185–94.
doi: 10.1172/JCI28549
23. Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, et al. ApoE
regulates hematopoietic stem cell proliferation, monocytosis, and monocyte
Frontiers in Endocrinology | www.frontiersin.org 10 April 2019 | Volume 10 | Article 204
Oguro Cholesterol Metabolism in Hematopoiesis
accumulation in atherosclerotic lesions in mice. J Clin Invest. (2011)
121:4138–49. doi: 10.1172/JCI57559
24. Feng Y, Schouteden S, Geenens R, Van Duppen V, Herijgers P, Holvoet P,
et al. Hematopoietic stem/progenitor cell proliferation and differentiation is
differentially regulated by high-density and low-density lipoproteins in mice.
PLoS ONE. (2012) 7:e47286. doi: 10.1371/journal.pone.0047286
25. Seijkens T, Hoeksema MA, Beckers L, Smeets E, Meiler S, Levels J,
et al. Hypercholesterolemia-induced priming of hematopoietic stem and
progenitor cells aggravates atherosclerosis. FASEB J. (2014) 28:2202–13.
doi: 10.1096/fj.13-243105
26. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M.
A targeted mutation in the murine gene encoding the high density
lipoprotein (HDL) receptor scavenger receptor class B type I reveals its
key role in HDL metabolism. Proc Natl Acad Sci USA. (1997) 94:12610–5.
doi: 10.1073/pnas.94.23.12610
27. Gao M, Zhao D, Schouteden S, Sorci-Thomas MG, Van Veldhoven
PP, Eggermont K, et al. Regulation of high-density lipoprotein on
hematopoietic stem/progenitor cells in atherosclerosis requires scavenger
receptor type BI expression.Arterioscler ThrombVasc Biol. (2014) 34:1900–9.
doi: 10.1161/ATVBAHA.114.304006
28. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, et al. Reactive
oxygen species act through p38 MAPK to limit the lifespan of hematopoietic
stem cells. Nat Med. (2006) 12:446–51. doi: 10.1038/nm1388
29. Tie G, Messina KE, Yan J, Messina JA, Messina LM. Hypercholesterolemia
induces oxidant stress that accelerates the ageing of hematopoietic stem cells.
J Am Heart Assoc. (2014) 3:e000241. doi: 10.1161/JAHA.113.000241
30. Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR.
ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ
Res. (2014) 114:157–70. doi: 10.1161/CIRCRESAHA.114.300738
31. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C,
Tall AR. Combined deficiency of ABCA1 and ABCG1 promotes foam cell
accumulation and accelerates atherosclerosis in mice. J Clin Invest. (2007)
117:3900–8. doi: 10.1172/JCI33372
32. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, et al.
ATP-binding cassette transporters and HDL suppress hematopoietic stem
cell proliferation. Science. (2010) 328:1689–93. doi: 10.1126/science.1189731
33. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S,
Levine RL, et al. Regulation of hematopoietic stem and progenitor cell
mobilization by cholesterol efflux pathways. Cell Stem Cell. (2012) 11:195–
206. doi: 10.1016/j.stem.2012.04.024
34. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C,
et al. T cell interleukin-17 induces stromal cells to produce proinflammatory
and hematopoietic cytokines. J Exp Med. (1996) 183:2593–603.
doi: 10.1084/jem.183.6.2593
35. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis
of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17.
Immunity. (2005) 22:285–94. doi: 10.1016/j.immuni.2005.01.011
36. Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler
I, et al. G-CSF potently inhibits osteoblast activity and CXCL12
mRNA expression in the bone marrow. Blood. (2005) 106:3020–7.
doi: 10.1182/blood-2004-01-0272
37. Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus
MS, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in
macrophages increases inflammation and accelerates atherosclerosis in mice.
Circ Res. (2013) 112:1456–65. doi: 10.1161/CIRCRESAHA.113.301086
38. Crysandt M, Hilgers RD, von Hobe S, Eisert A, Jost E, Panse J,
et al. Hypercholesterolemia and its association with enhanced stem cell
mobilization and harvest after high-dose cyclophosphamide+G-CSF. Bone
Marrow Transplant. (2011) 46:1426–9. doi: 10.1038/bmt.2010.327
39. Cimato TR, Palka BA, Lang JK, Young RF. LDL cholesterol modulates
human CD34+HSPCs through effects on proliferation and the IL-17 G-CSF
axis. PLoS ONE. (2013) 8:e73861. doi: 10.1371/journal.pone.0073861
40. Tolani S, Pagler TA, Murphy AJ, Bochem AE, Abramowicz S, Welch C,
et al. Hypercholesterolemia and reduced HDL-C promote hematopoietic
stem cell proliferation and monocytosis: studies in mice and FH children.
Atherosclerosis. (2013) 229:79–85. doi: 10.1016/j.atherosclerosis.2013.
03.031
41. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology
of human steroidogenesis and its disorders. Endocr Rev. (2011) 32:81–151.
doi: 10.1210/er.2010-0013
42. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev
Immunol. (2016) 16:626–38. doi: 10.1038/nri.2016.90
43. Viselli SM, Stanziale S, Shults K, Kovacs WJ, Olsen NJ. Castration
alters peripheral immune function in normal male mice. Immunology.
(1995) 84:337–42.
44. Wilson CA,Mrose SA, Thomas DW. Enhanced production of B lymphocytes
after castration. Blood. (1995) 85:1535–9.
45. Ellis TM,MoserMT, Le PT, Flanigan RC, Kwon ED. Alterations in peripheral
B cells and B cell progenitors following androgen ablation in mice. Int
Immunol. (2001) 13:553–8. doi: 10.1093/intimm/13.4.553
46. Viselli SM, Reese KR, Fan J, Kovacs WJ, Olsen NJ. Androgens alter B
cell development in normal male mice. Cell Immunol. (1997) 182:99–104.
doi: 10.1006/cimm.1997.1227
47. Smithson G, Couse JF, Lubahn DB, Korach KS, Kincade PW. The role of
estrogen receptors and androgen receptors in sex steroid regulation of B
lymphopoiesis. J Immunol. (1998) 161:27–34.
48. Olsen NJ, Watson MB, Kovacs WJ. Studies of immunological function in
mice with defective androgen action. Distinction between alterations in
immune function due to hormonal insensitivity and alterations due to other
genetic factors. Immunology. (1991) 73:52–7.
49. Olsen NJ, Watson MB, Henderson GS, Kovacs WJ. Androgen deprivation
induces phenotypic and functional changes in the thymus of adult malemice.
Endocrinology. (1991) 129:2471–6. doi: 10.1210/endo-129-5-2471
50. Olsen NJ, Olson G, Viselli SM, Gu X, Kovacs WJ. Androgen receptors
in thymic epithelium modulate thymus size and thymocyte development.
Endocrinology. (2001) 142:1278–83. doi: 10.1210/endo.142.3.8032
51. Olsen NJ, Gu X, Kovacs WJ. Bone marrow stromal cells mediate androgenic
suppression of B lymphocyte development. J Clin Invest. (2001) 108:1697–
704. doi: 10.1172/JCI200113183
52. Velardi E, Tsai JJ, Holland AM, Wertheimer T, Yu VW, Zakrzewski JL, et al.
Sex steroid blockade enhances thymopoiesis by modulating Notch signaling.
J Exp Med. (2014) 211:2341–9. doi: 10.1084/jem.20131289
53. Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune
system: is it ever too old to become young again? Nat Rev Immunol. (2009)
9:57–62. doi: 10.1038/nri2471
54. Dudakov JA, Goldberg GL, Reiseger JJ, Chidgey AP, Boyd RL.
Withdrawal of sex steroids reverses age- and chemotherapy-related
defects in bone marrow lymphopoiesis. J Immunol. (2009) 182:6247–60.
doi: 10.4049/jimmunol.0802446
55. Fitzpatrick FT, Kendall MD, Wheeler MJ, Adcock IM, Greenstein BD.
Reappearance of thymus of ageing rats after orchidectomy. J Endocrinol.
(1985) 106:R17–9. doi: 10.1677/joe.0.106R017
56. Goldberg GL, Sutherland JS, Hammet MV, Milton MK, Heng TS, Chidgey
AP, Boyd RL. Sex steroid ablation enhances lymphoid recovery following
autologous hematopoietic stem cell transplantation. Transplantation. (2005)
80:1604–13. doi: 10.1097/01.tp.0000183962.64777.da
57. Goldberg GL, Alpdogan O, Muriglan SJ, Hammett MV, Milton MK,
Eng JM, et al. Enhanced immune reconstitution by sex steroid ablation
following allogeneic hemopoietic stem cell transplantation. J Immunol.
(2007) 178:7473–84. doi: 10.4049/jimmunol.178.11.7473
58. Goldberg GL, King CG, Nejat RA, Suh DY, Smith OM, Bretz JC, et al.
Luteinizing hormone-releasing hormone enhances T cell recovery following
allogeneic bone marrow transplantation. J Immunol. (2009) 182:5846–54.
doi: 10.4049/jimmunol.0801458
59. Greenstein BD, Fitzpatrick FT, Adcock IM, Kendall MD, Wheeler
MJ. Reappearance of the thymus in old rats after orchidectomy:
inhibition of regeneration by testosterone. J Endocrinol. (1986) 110:417–22.
doi: 10.1677/joe.0.1100417
60. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP,
Heng TS, et al. Activation of thymic regeneration in mice and
humans following androgen blockade. J Immunol. (2005) 175:2741–53.
doi: 10.4049/jimmunol.175.4.2741
61. Goldberg GL, Dudakov JA, Reiseger JJ, Seach N, Ueno T, Vlahos K, et al.
Sex steroid ablation enhances immune reconstitution following cytotoxic
Frontiers in Endocrinology | www.frontiersin.org 11 April 2019 | Volume 10 | Article 204
Oguro Cholesterol Metabolism in Hematopoiesis
antineoplastic therapy in young mice. J Immunol. (2010) 184:6014–24.
doi: 10.4049/jimmunol.0802445
62. Dudakov JA, Goldberg GL, Reiseger JJ, Vlahos K, Chidgey AP, Boyd RL.
Sex steroid ablation enhances hematopoietic recovery following cytotoxic
antineoplastic therapy in aged mice. J Immunol. (2009) 183:7084–94.
doi: 10.4049/jimmunol.0900196
63. Khong DM, Dudakov JA, Hammett MV, Jurblum MI, Khong SM, Goldberg
GL, et al. Enhanced hematopoietic stem cell function mediates immune
regeneration following sex steroid blockade. Stem Cell Reports. (2015) 4:445–
58. doi: 10.1016/j.stemcr.2015.01.018
64. Rijhsinghani AG, Bhatia SK, Tygrett LT,Waldschmidt TJ. Effect of pregnancy
on thymic T cell development. Am J Reprod Immunol. (1996) 35:523–8.
doi: 10.1111/j.1600-0897.1996.tb00052.x
65. Medina KL, Smithson G, Kincade PW. Suppression of B lymphopoiesis
during normal pregnancy. J Exp Med. (1993) 178:1507–15.
doi: 10.1084/jem.178.5.1507
66. Erben RG, Raith S, Eberle J, Stangassinger M. Ovariectomy augments
B lymphopoiesis and generation of monocyte-macrophage precursors
in rat bone marrow. Am J Physiol. (1998) 274(3 Pt 1):E476–83.
doi: 10.1152/ajpendo.1998.274.3.E476
67. Miyaura C, Onoe Y, Inada M, Maki K, Ikuta K, Ito M, Suda T. Increased B-
lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian
function: similarity to estrogen deficiency. Proc Natl Acad Sci USA. (1997)
94:9360–5. doi: 10.1073/pnas.94.17.9360
68. Masuzawa T, Miyaura C, Onoe Y, Kusano K, Ohta H, Nozawa S, et al.
Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J
Clin Invest. (1994) 94:1090–7. doi: 10.1172/JCI117424
69. Smithson G, Beamer WG, Shultz KL, Christianson SW, Shultz LD,
Kincade PW. Increased B lymphopoiesis in genetically sex steroid-
deficient hypogonadal (hpg) mice. J Exp Med. (1994) 180:717–20.
doi: 10.1084/jem.180.2.717
70. Medina KL, Kincade PW. Pregnancy-related steroids are potential negative
regulators of B lymphopoiesis. Proc Natl Acad Sci USA. (1994) 91:5382–6.
doi: 10.1073/pnas.91.12.5382
71. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation,
proliferation, and survival of early B-lineage precursors. Blood.
(2000) 95:2059–67.
72. Medina KL, Garrett KP, Thompson LF, Rossi MI, Payne KJ, Kincade PW.
Identification of very early lymphoid precursors in bone marrow and their
regulation by estrogen. Nat Immunol. (2001) 2:718–24. doi: 10.1038/90659
73. Smithson G, Medina K, Ponting I, Kincade PW. Estrogen suppresses stromal
cell-dependent lymphopoiesis in culture. J Immunol. (1995) 155:3409–17.
74. Thurmond TS, Murante FG, Staples JE, Silverstone AE, Korach KS,
Gasiewicz TA. Role of estrogen receptor alpha in hematopoietic stem
cell development and B lymphocyte maturation in the male mouse.
Endocrinology. (2000) 141:2309–18. doi: 10.1210/endo.141.7.7560
75. Dukes PP, Goldwasser E. Inhibition of erythropoiesis by estrogens.
Endocrinology. (1961) 69:21–9. doi: 10.1210/endo-69-1-21
76. Mirand EA, Gordon AS. Mechanism of estrogen action in erythropoiesis.
Endocrinology. (1966) 78:325–32. doi: 10.1210/endo-78-2-325
77. Crafts RG. The effects of estrogens on the bone marrow of adult female dogs.
Blood. (1948) 3:276–85.
78. Schroeder C, Gibson L, Nordstrom C, Beug H. The estrogen receptor
cooperates with the TGF alpha receptor (c-erbB) in regulation of
chicken erythroid progenitor self-renewal. EMBO J. (1993) 12:951–60.
doi: 10.1002/j.1460-2075.1993.tb05736.x
79. Blobel GA, Sieff CA, Orkin SH. Ligand-dependent repression of the
erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell
Biol. (1995) 15:3147–53. doi: 10.1128/MCB.15.6.3147
80. Blobel GA, Orkin SH. Estrogen-induced apoptosis by inhibition of the
erythroid transcription factor GATA-1. Mol Cell Biol. (1996) 16:1687–94.
doi: 10.1128/MCB.16.4.1687
81. Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE. Estrogen
stimulates differentiation of megakaryocytes and modulates their expression
of estrogen receptors alpha and beta. J Cell Biochem. (2004) 92:249–57.
doi: 10.1002/jcb.20035
82. Du C, Xu Y, Yang K, Chen S, Wang X, Wang S, et al. Estrogen
promotes megakaryocyte polyploidization via estrogen receptor
beta-mediated transcription of GATA1. Leukemia. (2017) 31:945–56.
doi: 10.1038/leu.2016.285
83. Paharkova-Vatchkova V, Maldonado R, Kovats S. Estrogen preferentially
promotes the differentiation of CD11c+ CD11b(intermediate) dendritic
cells from bone marrow precursors. J Immunol. (2004) 172:1426–36.
doi: 10.4049/jimmunol.172.3.1426
84. Carreras E, Turner S, Frank MB, Knowlton N, Osban J, Centola M,
et al. Estrogen receptor signaling promotes dendritic cell differentiation
by increasing expression of the transcription factor IRF4. Blood. (2010)
115:238–46. doi: 10.1182/blood-2009-08-236935
85. Carreras E, Turner S, Paharkova-Vatchkova V, Mao A, Dascher C, Kovats S.
Estradiol acts directly on bone marrow myeloid progenitors to differentially
regulate GM-CSF or Flt3 ligand-mediated dendritic cell differentiation. J
Immunol. (2008) 180:727–38. doi: 10.4049/jimmunol.180.2.727
86. Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL,
et al. Clonal analysis unveils self-renewing lineage-restricted progenitors
generated directly from hematopoietic stem cells. Cell. (2013) 154:1112–26.
doi: 10.1016/j.cell.2013.08.007
87. Mahendroo MS, Cala KM, Landrum DP, Russell DW. Fetal death in mice
lacking 5alpha-reductase type 1 caused by estrogen excess. Mol Endocrinol.
(1997) 11:917–27.
88. Sheehan HL, Falkiner NM. Splenic aneurysm and splenic enlargement in
pregnancy. BrMed J. (1948) 2:1105. doi: 10.1136/bmj.2.4590.1105
89. Fowler JH, Nash DJ. Erythropoiesis in the spleen and bone
marrow of the pregnant mouse. Dev Biol. (1968) 18:331–53.
doi: 10.1016/0012-1606(68)90045-6
90. Illing A, Liu P, Ostermay S, Schilling A, de Haan G, Krust A,
et al. Estradiol increases hematopoietic stem and progenitor cells
independent of its actions on bone. Haematologica. (2012) 97:1131–5.
doi: 10.3324/haematol.2011.052456
91. Sanchez-Aguilera A, Arranz L, Martin-Perez D, Garcia-Garcia A,
Stavropoulou V, et al. Estrogen signaling selectively induces apoptosis
of hematopoietic progenitors and myeloid neoplasms without
harming steady-state hematopoiesis. Cell Stem Cell. (2014) 15:791–804.
doi: 10.1016/j.stem.2014.11.002
92. Notta F, Doulatov S, Dick JE. Engraftment of human hematopoietic stem
cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood.
(2010) 115:3704–7. doi: 10.1182/blood-2009-10-249326
93. Miller PH, Rabu G, MacAldaz M, Knapp DJ, Cheung AM, Dhillon K,
et al. Analysis of parameters that affect human hematopoietic cell outputs
in mutant c-kit-immunodeficient mice. Exp Hematol. (2017) 48:41–9.
doi: 10.1016/j.exphem.2016.12.012
94. Chapple RH, Hu T, Tseng YJ, Liu L, Kitano A, Luu V, et al. ERalpha
promotes murine hematopoietic regeneration through the Ire1alpha-
mediated unfolded protein response. Elife. (2018) 7. doi: 10.7554/eLife.31159
95. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB,
et al. Mangelsdorf DJ. 27-Hydroxycholesterol is an endogenous SERM that
inhibits the cardiovascular effects of estrogen. Nat Med. (2007) 13:1185–92.
doi: 10.1038/nm1641
96. Karuna R, Holleboom AG, Motazacker MM, Kuivenhoven JA,
Frikke-Schmidt R, Tybjaerg-Hansen A, et al. Plasma levels of 27-
hydroxycholesterol in humans and mice with monogenic disturbances
of high density lipoprotein metabolism. Atherosclerosis. (2011) 214:448–55.
doi: 10.1016/j.atherosclerosis.2010.10.042
97. Rosen H, Reshef A, Maeda N, Lippoldt A, Shpizen S, Triger L, et al. Markedly
reduced bile acid synthesis but maintained levels of cholesterol and vitamin
D metabolites in mice with disrupted sterol 27-hydroxylase gene. J Biol
Chem. (1998) 273:14805–12. doi: 10.1074/jbc.273.24.14805
98. WuQ, Ishikawa T, Sirianni R, TangH,McDonald JG, Yuhanna IS, et al. Shaul
PW. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast
cancer growth. Cell Rep. (2013) 5:637–45. doi: 10.1016/j.celrep.2013.10.006
99. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK,
et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer
pathophysiology. Science. (2013) 342:1094–8. doi: 10.1126/science.1241908
100. Umetani M, Ghosh P, Ishikawa T, Umetani J, Ahmed M, Mineo C, et al. The
cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via
proinflammatory processes mediated by estrogen receptor alpha. Cell Metab.
(2014) 20:172–82. doi: 10.1016/j.cmet.2014.05.013
Frontiers in Endocrinology | www.frontiersin.org 12 April 2019 | Volume 10 | Article 204
Oguro Cholesterol Metabolism in Hematopoiesis
101. Oguro H, McDonald JG, Zhao Z, Umetani M, Shaul PW, Morrison
SJ. 27-Hydroxycholesterol induces hematopoietic stem cell mobilization
and extramedullary hematopoiesis during pregnancy. J Clin Invest. (2017)
127:3392–401. doi: 10.1172/JCI94027
102. Ordovas JM, PocoviM, Grande F. Plasma lipids and cholesterol esterification
rate during pregnancy. Obstet Gynecol. (1984) 63:20–5.
103. Schwartz JA, Skafar DF. Ligand-mediated modulation of estrogen receptor
conformation by estradiol analogs. Biochemistry. (1993) 32:10109–15.
doi: 10.1021/bi00089a029
104. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM,
et al. Estrogen receptor (ER)modulators each induce distinct conformational
changes in ER alpha and ER beta. Proc Natl Acad Sci USA. (1999) 96:3999–
4004. doi: 10.1073/pnas.96.7.3999
105. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, Pace MC, et al. Coupling
of receptor conformation and ligand orientation determine graded activity.
Nat Chem Biol. (2010) 6:837–43. doi: 10.1038/nchembio.451
106. Wardell SE, Kazmin D, McDonnell DP. Research resource: transcriptional
profiling in a cellular model of breast cancer reveals functional and
mechanistic differences between clinically relevant SERM and between
SERM/estrogen complexes. Mol Endocrinol. (2012) 26:1235–48.
doi: 10.1210/me.2012-1031
107. DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-
hydroxycholesterol is an endogenous selective estrogen receptor modulator.
Mol Endocrinol. (2008) 22:65–77. doi: 10.1210/me.2007-0383
108. Feng Q, O’Malley BW. Nuclear receptor modulation–role of coregulators
in selective estrogen receptor modulator (SERM) actions. Steroids. (2014)
90:39–43. doi: 10.1016/j.steroids.2014.06.008
109. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in
metabolism. Cell Metab. (2013) 17:657–69. doi: 10.1016/j.cmet.2013.03.013
110. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO,
Gorgun CZ, Hotamisligil GS. chemical chaperones reduce ER stress and
restore glucose homeostasis in a mouse model of type 2 diabetes. Science.
(2006) 313:1137–40. doi: 10.1126/science.1128294
111. van Galen P, Kreso A, Wienholds E, Laurenti E, Eppert K, Lechman
ER, et al. Reduced lymphoid lineage priming promotes human
hematopoietic stem cell expansion. Cell Stem Cell. (2014) 14:94–106.
doi: 10.1016/j.stem.2013.11.021
112. Miharada K, Sigurdsson V, Karlsson S. Dppa5 improves hematopoietic stem
cell activity by reducing endoplasmic reticulum stress. Cell Rep. (2014)
7:1381–92. doi: 10.1016/j.celrep.2014.04.056
113. Ema H, Nakauchi H. Expansion of hematopoietic stem cells in the
developing liver of a mouse embryo. Blood. (2000) 95:2284–8.
114. Signer RA, Magee JA, Salic A, Morrison SJ. Haematopoietic stem cells
require a highly regulated protein synthesis rate. Nature. (2014) 509:49–54.
doi: 10.1038/nature13035
115. Sigurdsson V, Takei H, Soboleva S, Radulovic V, Galeev R, Siva K,
et al. Bile acids protect expanding hematopoietic stem cells from
unfolded protein stress in fetal liver. Cell Stem Cell. (2016) 18:522–32.
doi: 10.1016/j.stem.2016.01.002
116. Cyster JG, Dang EV, Reboldi A, Yi T. 25-Hydroxycholesterols in
innate and adaptive immunity. Nat Rev Immunol. (2014) 14:731–43.
doi: 10.1038/nri3755
117. Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G,
Russell DW. 25-Hydroxycholesterol secreted by macrophages in response to
Toll-like receptor activation suppresses immunoglobulin A production. Proc
Natl Acad Sci USA. (2009) 106:16764–9. doi: 10.1073/pnas.0909142106
118. Park K, Scott AL. Cholesterol 25-hydroxylase production by dendritic cells
and macrophages is regulated by type I interferons. J Leukoc Biol. (2010)
88:1081–7. doi: 10.1189/jlb.0610318
119. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT,
Rooyackers O, et al. Marked upregulation of cholesterol 25-hydroxylase
expression by lipopolysaccharide. J Lipid Res. (2009) 50:2258–64.
doi: 10.1194/jlr.M900107-JLR200
120. Zou T, Garifulin O, Berland R, Boyartchuk VL. Listeria monocytogenes
infection induces prosurvival metabolic signaling in macrophages. Infect
Immun. (2011) 79:1526–35. doi: 10.1128/IAI.01195-10
121. Reboldi A, Dang EV, McDonald JG, Liang G, Russell DW, Cyster
JG. Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven
inflammation downstream of type I interferon. Science. (2014) 345:679–84.
doi: 10.1126/science.1254790
122. Gold ES, Diercks AH, Podolsky I, Podyminogin RL, Askovich PS,
Treuting PM, Aderem A. 25-Hydroxycholesterol acts as an amplifier of
inflammatory signaling. Proc Natl Acad Sci USA. (2014) 111:10666–71.
doi: 10.1073/pnas.1404271111
123. Koarai A, Yanagisawa S, Sugiura H, Ichikawa T, Kikuchi T, Furukawa
K, et al. 25-Hydroxycholesterol enhances cytokine release and Toll-like
receptor 3 response in airway epithelial cells. Respir Res. (2012) 13:63.
doi: 10.1186/1465-9921-13-63
124. Dang EV, McDonald JG, Russell DW, Cyster JG. Oxysterol restraint of
cholesterol synthesis prevents AIM2 inflammasome activation. Cell. (2017)
171:1057–71 e11. doi: 10.1016/j.cell.2017.09.029
125. Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, et al.
The transcription factor STAT-1 couples macrophage synthesis of 25-
hydroxycholesterol to the interferon antiviral response. Immunity. (2013)
38:106–18. doi: 10.1016/j.immuni.2012.11.004
126. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, et al.
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry
by production of 25-hydroxycholesterol. Immunity. (2013) 38:92–105.
doi: 10.1016/j.immuni.2012.11.005
127. Gold ES, Ramsey SA, Sartain MJ, Selinummi J, Podolsky I, Rodriguez
DJ, et al. ATF3 protects against atherosclerosis by suppressing 25-
hydroxycholesterol-induced lipid body formation. J Exp Med. (2012)
209:807–17. doi: 10.1084/jem.20111202
128. Gatto D, Paus D, Basten A, Mackay CR, Brink R. Guidance of B cells by the
orphanG protein-coupled receptor EBI2 shapes humoral immune responses.
Immunity. (2009) 31:259–69. doi: 10.1016/j.immuni.2009.06.016
129. Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B cell segregation
between the outer and centre follicle. Nature. (2009) 460:1122–6.
doi: 10.1038/nature08226
130. Liu C, Yang XV, Wu J, Kuei C, Mani NS, Zhang L, et al. Oxysterols
direct B-cell migration through EBI2. Nature. (2011) 475:519–23.
doi: 10.1038/nature10226
131. Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, et al.
Oxysterols direct immune cell migration via EBI2.Nature. (2011) 475:524–7.
doi: 10.1038/nature10280
132. Gatto D, Wood K, Caminschi I, Murphy-Durland D, Schofield P, Christ D,
et al. The chemotactic receptor EBI2 regulates the homeostasis, localization
and immunological function of splenic dendritic cells. Nat Immunol. (2013)
14:446–53. doi: 10.1038/ni.2555
133. Yi T, Cyster JG. EBI2-mediated bridging channel positioning supports
splenic dendritic cell homeostasis and particulate antigen capture. Elife.
(2013) 2:e00757. doi: 10.7554/eLife.00757
134. Li J, Lu E, Yi T, Cyster JG. EBI2 augments Tfh cell fate by promoting
interaction with IL-2-quenching dendritic cells. Nature. (2016) 533:110–4.
doi: 10.1038/nature17947
135. Nevius E, Pinho F, Dhodapkar M, Jin H, Nadrah K, Horowitz MC, et al.
Oxysterols and EBI2 promote osteoclast precursor migration to bone
surfaces and regulate bone mass homeostasis. J Exp Med. (2015) 212:1931–
46. doi: 10.1084/jem.20150088
136. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein
(LDL) receptor activity in human acute myelogenous leukemia cells. Blood.
(1978) 52:1099–114.
137. Vitols S, Angelin B, Ericsson S, Gahrton G, Juliusson G, Masquelier
M, et al. Uptake of low density lipoproteins by human leukemic cells
in vivo: relation to plasma lipoprotein levels and possible relevance for
selective chemotherapy. Proc Natl Acad Sci USA. (1990) 87:2598–602.
doi: 10.1073/pnas.87.7.2598
138. Vitols S, Gahrton G, Bjorkholm M, Peterson C. Hypocholesterolaemia
in malignancy due to elevated low-density-lipoprotein-receptor activity in
tumour cells: evidence from studies in patients with leukaemia. Lancet.
(1985) 2:1150–4. doi: 10.1016/S0140-6736(85)92679-0
139. Scribano D, Baroni S, Pagano L, Zuppi C, Leone G, Giardina B. Return
to normal values of lipid pattern after effective chemotherapy in acute
lymphoblastic leukemia. Haematologica. (1996) 81:343–45.
140. Moschovi M, Trimis G, Apostolakou F, Papassotiriou I, Tzortzatou-
Stathopoulou F. Serum lipid alterations in acute lymphoblastic
Frontiers in Endocrinology | www.frontiersin.org 13 April 2019 | Volume 10 | Article 204
Oguro Cholesterol Metabolism in Hematopoiesis
leukemia of childhood. J Pediatr Hematol Oncol. (2004) 26:289–93.
doi: 10.1097/00043426-200405000-00006
141. Liebes LF, Pelle E, Zucker-Franklin D, Silber R. Comparison of lipid
composition and 1,6-diphenyl-1,3,5-hexatriene fluorescence polarization
measurements of hairy cells with monocytes and lymphocytes from normal
subjects and patients with chronic lymphocytic leukemia. Cancer Res.
(1981) 41:4050–6.
142. Yachnin S, Golomb HM, West EJ, Saffold C. Increased cholesterol
biosynthesis in leukemic cells from patients with hairy cell leukemia. Blood.
(1983) 61:50–60.
143. Golomb HM, Saffold CW, Nathans AH, Dawson G. Phospholipid and
cholesterol differences amongst leukemic cell types with special reference to
hairy cell leukemia: a preliminary report. Clin Chim Acta. (1981) 116:311–8.
doi: 10.1016/0009-8981(81)90050-4
144. Clutterbuck RD, Millar BC, Powles RL, Newman A, Catovsky D, Jarman M,
et al. Inhibitory effect of simvastatin on the proliferation of human myeloid
leukaemia cells in severe combined immunodeficient (SCID) mice. Br J
Haematol. (1998) 102:522–7. doi: 10.1046/j.1365-2141.1998.00783.x
145. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman
MH, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-
induced apoptosis: a potential therapeutic approach. Blood. (1999) 93:1308–
18.
146. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD,
Penn LZ. Lovastatin induces a pronounced differentiation response
in acute myeloid leukemias. Leuk Lymphoma. (2000) 40:167–78.
doi: 10.3109/10428190009054894
147. Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces
apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res
Commun. (1994) 199:1209–15. doi: 10.1006/bbrc.1994.1359
148. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by lovastatin through
activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol
Toxicol. (2000) 86:83–91. doi: 10.1034/j.1600-0773.2000.d01-16.x
149. Lishner M, Bar-Sef A, Elis A, Fabian I. Effect of simvastatin alone
and in combination with cytosine arabinoside on the proliferation
of myeloid leukemia cell lines. J Investig Med. (2001) 49:319–24.
doi: 10.2310/6650.2001.33896
150. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ.
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than
lovastatin. Clin Cancer Res. (2001) 7:2067–75.
151. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in
human cancer cells.Mol Cancer Ther. (2001) 1:141–9.
152. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-
modulating agents kill acute myeloid leukemia cells and sensitize them
to therapeutics by blocking adaptive cholesterol responses. Blood. (2003)
101:3628–34. doi: 10.1182/blood-2002-07-2283
153. Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A,
et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines
to lovastatin. Leukemia. (2000) 14:1444–50. doi: 10.1038/sj.leu.2401856
154. Newman A, Clutterbuck RD, Powles RL, Millar JL. Selective inhibition of
primary acute myeloid leukaemia cell growth by simvastatin. Leukemia.
(1994) 8:2023–9.
155. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, et al.
Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer
Res. (2007) 67:4524–32. doi: 10.1158/0008-5472.CAN-06-3686
156. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE.
Mevastatin can increase toxicity in primary AMLs exposed to standard
therapeutic agents, but statin efficacy is not simply associated with
ras hotspot mutations or overexpression. Leuk Res. (2003) 27:133–45.
doi: 10.1016/S0145-2126(02)00085-1
157. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ.
Blocking protein geranylgeranylation is essential for lovastatin-induced
apoptosis of human acute myeloid leukemia cells. Leukemia. (2001) 15:1398–
407. doi: 10.1038/sj.leu.2402196
158. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking
the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia
cells to lovastatin-induced apoptosis. Cancer Res. (2004) 64:6461–8.
doi: 10.1158/0008-5472.CAN-04-0866
159. Chen R, Xiao W, Li D, Mu S. Combination of simvastatin and imatinib
sensitizes the CD34+ cells in K562 to cell death.Med Oncol. (2011) 28:528–
31. doi: 10.1007/s12032-010-9472-9
160. Yang YC, Xiao DW, Liu H, Chuan LM, Zeng YL, Zhou DA, Liu W, Xu
GQ, Huang WF. Mechanism of simvastatin-induced K562 cell apoptosis.
Pharmacology. (2009) 84:191–5. doi: 10.1159/000235907
161. Oh B, Kim TY, Min HJ, Kim M, Kang MS, Huh JY, Kim Y, Lee DS.
Synergistic killing effect of imatinib and simvastatin on imatinib-resistant
chronic myelogenous leukemia cells. Anticancer Drugs. (2013) 24:20–31.
doi: 10.1097/CAD.0b013e32835a0fbd
162. Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-
V617F-mediated signalling is dependent on lipid rafts and statins inhibit
JAK2-V617F-dependent cell growth. Br J Haematol. (2013) 160:177–87.
doi: 10.1111/bjh.12103
163. Yasuda N, Matzno S, Iwano C, Nishikata M, Matsuyama K. Evaluation
of apoptosis and necrosis induced by statins using fluorescence-
enhanced flow cytometry. J Pharm Biomed Anal. (2005) 39:712–7.
doi: 10.1016/j.jpba.2005.04.022
164. Sheen C, Vincent T, Barrett D, Horwitz EM, Hulitt J, Strong E, Grupp SA,
Teachey DT. Statins are active in acute lymphoblastic leukaemia (ALL): a
therapy that may treat ALL and prevent avascular necrosis. Br J Haematol.
(2011) 155:403–7. doi: 10.1111/j.1365-2141.2011.08696.x
165. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner
M. Simvastatin induces apoptosis of B-CLL cells by activation
of mitochondrial caspase 9. Exp Hematol. (2003) 31:779–83.
doi: 10.1016/S0301-472X(03)00192-9
166. Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszynska
A. Simvastatin and purine analogs have a synergic effect on apoptosis
of chronic lymphocytic leukemia cells. Ann Hematol. (2010) 89:1115–24.
doi: 10.1007/s00277-010-0988-z
167. Vitols S, Angelin B, Juliusson G. Simvastatin impairs mitogen-induced
proliferation of malignant B-lymphocytes from humans–in vitro and in vivo
studies. Lipids. (1997) 32:255–62. doi: 10.1007/s11745-997-0032-1
168. Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H, Amet T, et al. Role
for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell
Res. (2009) 315:141–50. doi: 10.1016/j.yexcr.2008.10.010
169. Rozados VR, Hinrichsen LI, Binda MM, Gervasoni SI, Matar P, Bonfil
RD, et al. Lovastatin enhances the antitumoral and apoptotic activity
of doxorubicin in murine tumor models. Oncol Rep. (2008) 19:1205–11.
doi: 10.3892/or.19.5.1205
170. van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel
B, Bloem AC, et al. Protein geranylgeranylation is critical for the regulation
of survival and proliferation of lymphoma tumor cells. Clin Cancer Res.
(2003) 9:5735–48.
171. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the
mitochondrial pathway of apoptosis in human lymphoblasts and myeloma
cells. Carcinogenesis. (2005) 26:883–91. doi: 10.1093/carcin/bgi036
172. Dmoszynska A, Podhorecka M, Klimek P, Grzasko N. Lovastatin and
thalidomide have a combined effect on the rate of multiple myeloma cell
apoptosis in short term cell cultures. Eur J Clin Pharmacol. (2006) 62:325–9.
doi: 10.1007/s00228-006-0106-2
173. Gronich N, Drucker L, Shapiro H, Radnay J, Yarkoni S, Lishner M.
Simvastatin induces death of multiple myeloma cell lines. J Investig Med.
(2004) 52:335–44. doi: 10.1136/jim-52-05-34
174. Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, et al.
Thalidomide, dexamethasone and lovastatin with autologous stem cell
transplantation as a salvage immunomodulatory therapy in patients with
relapsed and refractory multiple myeloma. Ann Hematol. (2011) 90:1161–6.
doi: 10.1007/s00277-011-1276-2
175. van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer
L, van de Donk NW. Inhibition of the mevalonate pathway potentiates
the effects of lenalidomide in myeloma. Leuk Res. (2009) 33:100–8.
doi: 10.1016/j.leukres.2008.06.001
176. van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem
AC. Inhibition of protein geranylgeranylation induces apoptosis in myeloma
plasma cells by reducing Mcl-1 protein levels. Blood. (2003) 102:3354–62.
doi: 10.1182/blood-2003-03-0970
Frontiers in Endocrinology | www.frontiersin.org 14 April 2019 | Volume 10 | Article 204
Oguro Cholesterol Metabolism in Hematopoiesis
177. Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, et al.
Niche-based screening identifies small-molecule inhibitors of leukemia stem
cells. Nat Chem Biol. (2013) 9:840–8. doi: 10.1038/nchembio.1367
178. Christ M, Luu B, Mejia JE, Moosbrugger I, Bischoff P. Apoptosis induced
by oxysterols in murine lymphoma cells and in normal thymocytes.
Immunology. (1993) 78:455–60.
179. Hwang PL. Inhibitors of protein and RNA synthesis block the cytotoxic
effects of oxygenated sterols. Biochim Biophys Acta. (1992) 1136:5–11.
doi: 10.1016/0167-4889(92)90077-O
180. Hietter H, Bischoff P, Beck JP, Ourisson G, Luu B. Comparative effects
of 7 beta-hydroxycholesterol towards murine lymphomas, lymphoblasts
and lymphocytes: selective cytotoxicity and blastogenesis inhibition. Cancer
Biochem Biophys. (1986) 9:75–83.
181. Rosa Fernandes L, Stern AC, Cavaglieri RC, Nogueira FC, Domont G,
et al. 7-Ketocholesterol overcomes drug resistance in chronic myeloid
leukemia cell lines beyond MDR1 mechanism. J Proteomics. (2017) 151:12–
23. doi: 10.1016/j.jprot.2016.06.011
182. Aupeix K, Weltin D, Mejia JE, Christ M, Marchal J, Freyssinet JM,
et al. Oxysterol-induced apoptosis in human monocytic cell lines.
Immunobiology. (1995) 194:415–28. doi: 10.1016/S0171-2985(11)
80108-7
183. Lim HK, Kang HK, Yoo ES, Kim BJ, Kim YW, Cho M, et al.
Oxysterols induce apoptosis and accumulation of cell cycle at G/M phase
in the human monocytic THP-1 cell line. Life Sci. (2003) 72:1389–99.
doi: 10.1016/S0024-3205(02)02377-9
184. Tsujioka T, Yokoi A, Itano Y, Takahashi K, Ouchida M, Okamoto S,
et al. Five-aza-2′-deoxycytidine-induced hypomethylation of cholesterol 25-
hydroxylase gene is responsible for cell death of myelodysplasia/leukemia
cells. Sci Rep. (2015) 5:16709. doi: 10.1038/srep16709
185. Bonig H, Papayannopoulou T. Hematopoietic stem cell mobilization:
updated conceptual renditions. Leukemia. (2013) 27:24–31.
doi: 10.1038/leu.2012.254
186. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al.
Optimizing autologous stem cell mobilization strategies to improve patient
outcomes: consensus guidelines and recommendations. Biol Blood Marrow
Transplant. (2014) 20:295–308. doi: 10.1016/j.bbmt.2013.10.013
187. Tabas I, Lichtman AH. Monocyte-macrophages and T
cells in atherosclerosis. Immunity. (2017) 47:621–34.
doi: 10.1016/j.immuni.2017.09.008
188. Nahrendorf M. Myeloid cell contributions to cardiovascular health and
disease. Nat Med. (2018) 24:711–20. doi: 10.1038/s41591-018-0064-0
189. Zmyslowski A, Szterk A. Current knowledge on the mechanism of
atherosclerosis and pro-atherosclerotic properties of oxysterols. Lipids
Health Dis. (2017) 16:188. doi: 10.1186/s12944-017-0579-2
190. Nofer JR. Estrogens and atherosclerosis: insights from animal models and
cell systems. J Mol Endocrinol. (2012) 48:R13–29. doi: 10.1530/JME-11-0145
191. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al.
Myocardial infarction accelerates atherosclerosis. Nature. (2012) 487:325–9.
doi: 10.1038/nature11260
192. Dutta P, Sager HB, Stengel KR, Naxerova K, Courties G, Saez
B, et al. Myocardial infarction activates CCR2(+) hematopoietic
stem and progenitor cells. Cell Stem Cell. (2015) 16:477–87.
doi: 10.1016/j.stem.2015.04.008
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Oguro. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 15 April 2019 | Volume 10 | Article 204
